Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Generic Dasatinib vs Sprycel
NCT05640804Phase 1Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Sep 2018
- Primary completion
- Oct 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dasatinib in chronic myelogenous leukemia (CML) (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Maximum Plasma Concentration at 24 hours, Area Under the Curve (0-t) at 24 hours and 1 more. Started Sep 2018; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT05640804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05640804.